Brief: Roche Presents Phase III Data Showing 55% Relapse-Rate Reduction For MS Drug Fenebrutinib
Wed 13:03
BRIEF-Roche Presents Phase III Data Showing 55% Relapse-Rate Reduction For MS Drug Fenebrutinib Oct 21 (Reuters) - ROCHE HOLDING AG ROPC.S:
ROCHE PRESENTS NEW PIVOTAL TRIAL DATA ACROSS BROAD NEUROIMMUNOLOGY PORTFOLIO AT MSTORONTO2026
ENSPRYNG PHASE III DATA SHOW SIGNIFICANT ATTACK REDUCTION AND IMPROVED FUNCTIONAL RECOVERY IN MOGAD
FENEBRUTINIB FENHANCE 1 & 2 PHASE III POOLED DATA SHOW A 55% REDUCTION IN ANNUALISED RELAPSE RATE (ARR) VERSUS ACTIVE COMPARATOR
75% OF FENEBRUTINIB-TREATED PATIENTS SHOW NO EVIDENCE OF DISEASE ACTIVITY AT TWO YEARS
FENEBRUTINIB PHASE III DATA SHOW 55% REDUCTION IN ANNUALISED RELAPSE RATE VERSUS COMPARATOR
Source text: ID:nGNE3gJkWs
Further company coverage: ROPC.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey